secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001437749-24-014062
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M
--------------------------------------------------------------------------

- BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.
- Net loss improved to $10.7M from $39.2M in Q1 2023; cash position $209.8M as of March 31, 2024.
- Raised FY 2024 BRIUMVI U.S. net revenue guidance to $270-290M (prior $220-260M) with Q2 target ~$65M.
- Over 1,250 new BRIUMVI prescriptions in Q1; VA national formulary contract secured for anti-CD20 indications.
- R&D spend $32.7M includes $8.8M license fee for azer-cel allogeneic CAR-T from Precision BioSciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/0001437749-24-014062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/tgtx20240430_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-014062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer